Post-infectious ibs following Clostridioides difficile infection; role of microbiota and implications for treatment
Digestive and Liver Disease · 2024-11 · 56 (11) · 1805-1809
DOI: 10.1016/j.dld.2024.03.008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Digestive and Liver Disease, 2024-11. Verfasst von Dana Taghaddos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Clostridium Infections, Fecal Microbiota Transplantation, Gastrointestinal Microbiome. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: W. Garfield Weston Foundation, Canadian Institutes of Health Research, W Garfield Weston Foundation.
Abstract (Originalsprache)
Up to 25% of patients recovering from antibiotic-treated Clostridioides difficile infection (CDI) develop functional symptoms reminiscent of Post-Infectious Irritable Bowel Syndrome (PI-IBS). For patients with persistent symptoms following infection, a clinical dilemma arises as to whether to provide additional antibiotic treatment or to adopt a conservative symptom-based approach. Here, we review the literature on CDI-related PI-IBS and compare the findings with PI-IBS. We review proposed mechanisms, including the role of C. difficile toxins and the microbiota, and discuss implications for therapy. We suggest that gut dysfunction post-CDI may be initiated by toxin-induced damage to enteroglial cells and that a dysbiotic gut microbitota maintains the clinical phenotype over time, prompting consideration of microbiota-directed therapies. While Fecal Microbial Transplant (FMT) is currently reserved for recurrent CDI (rCDI), we propose that microbiota-directed therapies may have a role in primary CDI in order to avoid or mitigate futher antibiotic treatment that further disrupts the microbiota and thus prevent PI-IBS. We discuss novel microbial transfer therapies and as they emerge, we recommend clinical trials to determine whether microbial transfer therapy of the primary infection prevents both rCDI and CDI-related PI- IBS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
- Division of Gastroenterology, Kyushu University, Japan.
- Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada. Electronic address: scollins@mcmaster.ca.
Förderung
- W. Garfield Weston Foundation
- Canadian Institutes of Health Research
- W Garfield Weston Foundation
Zitieren
APA
Taghaddos, D., Saqib, Z., Bai, X., Bercik, P., & Collins, S. M. (2024). Post-infectious ibs following Clostridioides difficile infection; role of microbiota and implications for treatment. Digestive and Liver Disease, 56(11), 1805-1809. https://doi.org/10.1016/j.dld.2024.03.008
Vancouver
Taghaddos D, Saqib Z, Bai X, Bercik P, Collins SM. Post-infectious ibs following Clostridioides difficile infection; role of microbiota and implications for treatment. Digestive and Liver Disease. 2024;56(11):1805-1809. doi:10.1016/j.dld.2024.03.008
BibTeX
@article{Taghaddos2024,
author = {Taghaddos, Dana and Saqib, Zarwa and Bai, Xiaopeng and Bercik, Premysl and Collins, Stephen M},
title = {Post-infectious ibs following Clostridioides difficile infection; role of microbiota and implications for treatment},
journal = {Digestive and Liver Disease},
year = {2024},
volume = {56},
number = {11},
pages = {1805--1809},
doi = {10.1016/j.dld.2024.03.008}
}
EUVIMED